Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm 17176, Sweden.
GE Healthcare Pharmaceutical Diagnostics, Little Chalfont HP8 4SP, United Kingdom.
ACS Chem Neurosci. 2020 Dec 16;11(24):4398-4404. doi: 10.1021/acschemneuro.0c00631. Epub 2020 Dec 7.
Monoamine oxidase B (MAO-B) is an important enzyme regulating the levels of monoaminergic neurotransmitters. Selective MAO-B inhibitors have been labeled with carbon-11 or fluorine-18 to visualize the localization of MAO-B by positron emission tomography (PET) and thereby have been useful for studying neurodegenerative diseases. The aim of this study was to develop promising fluorine-18 labeled reversible MAO-B PET radioligands and their biological evaluation by autoradiography. Radiolabeling was achieved by classical one-step fluorine-18 nucleophilic substitution reaction. The stability and radiochemical yield was analyzed with HPLC. All five fluorine-18 labeled compounds were tested in human whole hemisphere autoradiography experiments. Five compounds (GEH200439, GEH200448, GEH200449, GEH200431A, and GEH200431B) were successfully radiolabeled with fluorine-18, and the incorporation yield of the fluorination reactions varied from 10 to 45% depending on the compound. The radiochemical purity was higher than 99% for all at the end of synthesis. Radioligands were found to be stable, with a radiochemical purity of >99% in a sterile phosphate buffered saline (pH = 7.4) over the duration of the study. The ARG binding density of only F-GEH200449 was consistent with known MAO-B expression in the human brain. Radiolabeling of five new fluorine-18 MAO-B reversible inhibitors was successfully accomplished. Compound F-GEH200449 binds specifically to MAO-B postmortem brain and could be a potential candidate for PET investigation.
单胺氧化酶 B(MAO-B)是调节单胺能神经递质水平的重要酶。已用碳-11 或氟-18 标记选择性 MAO-B 抑制剂,通过正电子发射断层扫描(PET)来可视化 MAO-B 的定位,从而有助于研究神经退行性疾病。本研究旨在开发有前途的氟-18 标记的可逆 MAO-B PET 放射性配体,并通过放射自显影对其进行生物学评估。放射性标记是通过经典的一步氟-18 亲核取代反应实现的。使用 HPLC 分析了稳定性和放射化学产率。在人类整个脑半球放射自显影实验中测试了所有五种氟-18 标记化合物。成功地用氟-18 标记了五种化合物(GEH200439、GEH200448、GEH200449、GEH200431A 和 GEH200431B),根据化合物的不同,氟代反应的掺入产率从 10%到 45%不等。在合成结束时,所有产物的放射化学纯度均高于 99%。研究期间,在无菌磷酸盐缓冲盐水(pH = 7.4)中,放射性配体稳定,放射化学纯度>99%。只有 F-GEH200449 的 ARG 结合密度与已知的人类大脑中的 MAO-B 表达一致。成功地完成了五种新的氟-18 MAO-B 可逆抑制剂的放射性标记。化合物 F-GEH200449 特异性结合死后大脑中的 MAO-B,可能是 PET 研究的潜在候选物。